167 related articles for article (PubMed ID: 10519380)
21. Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer.
Ralhan R; Agarwal S; Mathur M; Wasylyk B; Srivastava A
Clin Cancer Res; 2000 Jun; 6(6):2440-7. PubMed ID: 10873097
[TBL] [Abstract][Full Text] [Related]
22. Selection of cell death-deficient p53 mutants in Saccharomyces cerevisiae.
Yacoubi-Hadj Amor I; Smaoui K; Belguith H; Djemal L; Dardouri M; Mokdad-Gargouri R; Gargouri A
Yeast; 2009 Aug; 26(8):441-50. PubMed ID: 19579214
[TBL] [Abstract][Full Text] [Related]
23. Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant.
Klein MA; Rüedi D; Nozaki M; Dell EW; Diserens AC; Seelentag W; Janzer RC; Aguzzi A; Hegi ME
Oncogene; 2000 Nov; 19(47):5329-37. PubMed ID: 11103934
[TBL] [Abstract][Full Text] [Related]
24. Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation.
Leung SY; Yuen ST; Chan TL; Chan AS; Ho JW; Kwan K; Fan YW; Hung KN; Chung LP; Wyllie AH
Oncogene; 2000 Aug; 19(35):4079-83. PubMed ID: 10962567
[TBL] [Abstract][Full Text] [Related]
25. Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
Bartussek C; Naumann U; Weller M
Exp Cell Res; 1999 Dec; 253(2):432-9. PubMed ID: 10585266
[TBL] [Abstract][Full Text] [Related]
26. Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings.
Khan Z; Tiwari RP; Mulherkar R; Sah NK; Prasad GB; Shrivastava BR; Bisen PS
Head Neck; 2009 Aug; 31(8):1039-48. PubMed ID: 19340865
[TBL] [Abstract][Full Text] [Related]
27. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
28. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants.
Waterman MJ; Waterman JL; Halazonetis TD
Cancer Res; 1996 Jan; 56(1):158-63. PubMed ID: 8548757
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal study of TP53 mutations in eight patients with potentially malignant oral mucosal disorders.
Ogmundsdóttir HM; Hilmarsdóttir H; Björnsson J; Holbrook WP
J Oral Pathol Med; 2009 Oct; 38(9):716-21. PubMed ID: 19473449
[TBL] [Abstract][Full Text] [Related]
30. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
31. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
32. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
33. [Functional restoration of tumor suppressor p53 alters susceptibility of glioblastoma cells to irradiation--analysis using a cell line containing a temperature-sensitive mutant].
Tsuchiya K
Hokkaido Igaku Zasshi; 2000 Jul; 75(4):265-74. PubMed ID: 10976406
[TBL] [Abstract][Full Text] [Related]
34. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
[TBL] [Abstract][Full Text] [Related]
35. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.
Deissler H; Kafka A; Schuster E; Sauer G; Kreienberg R; Zeillinger R
Oncol Rep; 2004 Jun; 11(6):1281-6. PubMed ID: 15138567
[TBL] [Abstract][Full Text] [Related]
36. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
Homma T; Fukushima T; Vaccarella S; Yonekawa Y; Di Patre PL; Franceschi S; Ohgaki H
J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
[TBL] [Abstract][Full Text] [Related]
37. Transforming activity of mutant human p53 alleles.
Slingerland JM; Benchimol S
J Cell Physiol; 1991 Sep; 148(3):391-5. PubMed ID: 1918170
[TBL] [Abstract][Full Text] [Related]
38. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract.
Waridel F; Estreicher A; Bron L; Flaman JM; Fontolliet C; Monnier P; Frebourg T; Iggo R
Oncogene; 1997 Jan; 14(2):163-9. PubMed ID: 9010218
[TBL] [Abstract][Full Text] [Related]
39. Functional analysis of p53 tumor suppressor in yeast.
Smardová J; Smarda J; Koptíková J
Differentiation; 2005 Jul; 73(6):261-77. PubMed ID: 16138827
[TBL] [Abstract][Full Text] [Related]
40. Patient with multiple primary carcinomas including 4 separate oral cancers: study of p53 mutations and their implications for management.
Fukuda M; Nakatsuka T; Kusama K; Sakashita H
J Oral Maxillofac Surg; 2006 Nov; 64(11):1672-9. PubMed ID: 17052595
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
